A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2017
At a glance
- Drugs CERE 110 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Ceregene
- 22 Apr 2015 According to a company media release, Sangamo BioSciences has terminated the CERE-110 program.
- 22 Apr 2015 Status changed from active, no longer recruiting to completed according to a Sangamo BioSciences media release.
- 26 Aug 2013 Results are now expected in 2015 according to a Sangamo Biosciences, who acquired Ceregene, as announced in a company media release. Patients are presently in the follow-up stage.